Home Newsfeeds Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $8

Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $8

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $2 to $8.

byBenzinga Newsdesk

November 11, 2022

1 minute read

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $2 to $8.

Bowlero Analysts Slash Their Forecasts After Q3 Results

By Avi Kapoor

May 7, 9:07 AM

Bowlero Corp. (NYSE:BOWL) reported worse-than-expected third-quarter sales results on Monday. Bowlero posted GAAP earnings of 13 cents per…

BOWL

Oracle Stock Is Moving Higher Monday: What’s Going On?

By Adam Eckert

June 12, 9:32 AM

Oracle Corp (NYSE: ORCL) shares are trading higher Monday after Wolfe Research upgraded the stock ahead of the company's quarterly results. Multiple analysts also raised price targets at the end of last week.

ORCL

Pfizer Canada Announces LITFULO Receives Health Canada Approval, Becoming The First Approved Treatment For Severe Alopecia Areata In Canada

By Benzinga Newsdesk

December 4, 12:05 PM

A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata.KIRKLAND, QC, Dec. 4, 2023 /CNW/ - Today, Pfizer Canada

PFE

Zebra Technologies CEO Addresses Q3 Challenges as Segment Sales Dip

By Anusuya Lahiri

October 31, 9:36 AM

Zebra Technologies Corp (NASDAQ: ZBRA) reported a third-quarter FY23 net sales decline of 30.6% year-on-year to $956 million, beating the

CSCO

Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $8

Related Posts

Bowlero Analysts Slash Their Forecasts After Q3 Results

Oracle Stock Is Moving Higher Monday: What’s Going On?

Pfizer Canada Announces LITFULO Receives Health Canada Approval, Becoming The First Approved Treatment For Severe Alopecia Areata In Canada

Zebra Technologies CEO Addresses Q3 Challenges as Segment Sales Dip